Navigation Links
MRC Technology Enters Into an Exclusive License Agreement With Genentech
Date:7/11/2010

LONDON, July 12, 2010 /PRNewswire/ -- MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease.

This is the first small molecule chemistry programme to come out of MRC Technology's Centre for Therapeutics Discovery (CTD) and the first major small molecule collaboration the CTD has formed with an industry partner.

Under the terms of the agreement, MRC Technology will receive an upfront payment and is eligible to receive clinical development milestone payments and royalties on sales. Full financial terms and the target of the small molecule project have not been disclosed.

Working with investigators funded through UK's Medical Research Council, MRC Technology's CTD initiated a small molecule drug discovery programme that included medicinal chemistry, biology, analytical and DMPK Computational Chemistry. CTD was formed one year ago from the MRC Technology Drug Discovery Group, expanding its capability and capacity to provide the UK with a national drug discovery resource with the critical mass to progress high quality projects towards clinical benefit. MRC Technology works with targets not only from the UK's Medical Research Council but has a pipeline of targets from academic organisations worldwide.

Dr Dave Tapolczay, CEO of MRC Technology, said, "We are delighted that we have been able to partner this programme with Genentech, and extremely pleased that the terms of our agreement reflect the value of the small molecule drug discovery programme and support our innovative
'/>"/>

SOURCE MRC Technology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
3. Yongye Biotechnology International Retains CCG Investor Relations
4. William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology
5. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
6. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
7. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
8. Yongye Biotechnology International Announces Second Quarter Results
9. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
10. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The ... the use of special anti-vascular endothelial growth factor agents given by injection into ... does not have a scientific protocol for the many millions diagnosed with it. ...
(Date:9/2/2015)... 2015 Research and Markets ... PharmaBiotech,s new report "Gene Therapy - Technologies, Markets ... markets for gene therapy are difficult to estimate as ... it is marketed in China ... years 2014-2024. The estimates are based on epidemiology of ...
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... Point of Preventing Bacterial Colonization with ... Leader, VANCOUVER, March 18 /PRNewswire-FirstCall/ - ... ANP), a global specialty pharmaceutical and,medical device ... from its 960,patient clinical trial comparing its ...
... RainDance Technologies, Inc.,a developer of NanoReactor ... Stephen E. Becker as Vice President,Commercial Officer, ... responsible for continuing the growth of the,company,s ... launch of its first,life science offering," said ...
... AAAAI 64th Annual Meeting also show that C1-INH is ... HAE attacks across all body sites, PHILADELPHIA, March ... effective therapy that rapidly relieves acute,abdominal and facial swelling ... serious genetic disorder, according to data,presented today at the ...
Cached Biology Technology:960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7RainDance Appoints Becker Chief Commercial Officer 2RainDance Appoints Becker Chief Commercial Officer 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
(Date:8/4/2015)... -- AMRI (NASDAQ: AMRI ) today reported financial and operating results ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, with ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... redundant portions of the fruit fly genome may not ... from a Princeton-led team of researchers suggest that repeated ... normal development under less-than-ideal growth conditions by making sure ... appropriate times. If similar regions are found in humans, ...
... estimated to afflict as many as 12 million people worldwide ... vulnerable to compounds developed to treat cancer and other disorders, ... have found. Scientists searched the genome of the parasite ... of TOR kinases, proteins that are linked to cell growth ...
... SPOKANE, Wash.Washington State University researchers have discovered a way to ... for slowing and even stopping the growth of tumors. "Hopefully, ... Weihang Chai, an assistant professor in the WSU School of ... "Basically, you make the cancer cell go from immortal to ...
Cached Biology News:Redundant genetic instructions in 'junk DNA' support healthy development 2Redundant genetic instructions in 'junk DNA' support healthy development 3Redundant genetic instructions in 'junk DNA' support healthy development 4Cancer drugs may help stop major parasite 2
RABBIT ANTI HALOPERIDOL...
Form: Ready to use Applications: Western Blot, ELISA...
... Bench-Top Open System Chemistry Analyzer for General Chemistries, Specialty Chemistries, QC, Reagent Development, Pharmaceutical ... grating, diode spectrophotometer over 30 user-selectable wavelengths. ... ... ...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: